Skip to main content
Menu

Posts tagged with "Business and Markets"

  • Business and Markets

    Revenues From New Drugs – And Thoughts on Chance

    Here’s an interesting analysis of the industry from IDEA Pharma, via Endpoints. They’re looking at the revenues from the more recent drugs in the pipeline (approved in the last five years) and comparing that to each company’s total R&D spending. The list is all Big Pharma – the cutoff is companies that have at least… Read More
  • Business and Markets

    AbbVie, Allergan, Ugh

    News broke yesterday morning (first at the Wall Street Journal, I believe) that Abbvie has agreed to acquire Allergan. This is one of the larger pharma mergers of recent years, and regular readers of this site will have a pretty good idea of the sigh and roll of the eyes with which I greet it. Read More
  • Academia (vs. Industry)

    Innovation, at Universities and in Industry

    Some thoughts this morning on universities and industry and their contributions to research – and for once, this isn’t going to be another long screed on drug research in particular. No, I’m particularly talking about what each of these brings to R&D in general, and about the places (both conceptual and physical) where they se… Read More
  • Alzheimer's Disease

    A Missed Alzheimer’s Opportunity? Not So Much

    The Washington Post made quite a splash with this story about Pfizer, Enbrel (etanercept), and Alzheimer’s disease. There’s already been a lot of comment about it yesterday on Twitter and in some other venues, but I thought it might be useful to try to sum things up in an easily accessible place. Here we go: Read More
  • Biological News

    Antibody Design, Publicly Challenged

    Comes now some rather disturbing news in the antibody field. These things are extremely important, both as therapeutics and as research reagents, and developing them for either purpose is no stroll down the garden walk. There are a number of techniques for raising and producing antibodies (see that first link), but they all have their… Read More
  • Business and Markets

    Catalyst and Jacobus and LEMS: The Latest Chapter

    I last wrote about the situation with Catalyst Pharmaceuticals here last December when Firdapse, their drug for Lambert-Eaton myasthenic syndrome, was approved by the FDA. If you know the story, though (or follow the links in that post) you’ll see that referring to it as “their drug” is a rather legalistic way of looking at thing… Read More
  • Business and Markets

    The Going Rates, 2019 Edition

    I did a post a few years ago that was a sort of informal salary survey for biopharma folks (I asked initially about the Boston/Cambridge area, but responses came in from many other places as well). I’ve had a recent request for an update, and I think it would make an interesting comparison.. So break… Read More
  • Business and Markets

    Big Pharma Cuts, Current and Coming

    Word came out just before the weekend (first at Endpoints) that GlaxoSmithKline is laying off R&D employees at both Stevenage (UK) and Upper Providence (US). Current leadership is re-organizing drug discovery efforts to put more emphasis on oncology, immunology and genetic-linked disease, and this moves seems linked to that. Reports are that ov… Read More
  • Business and Markets

    Sorrento Therapeutics Is Not Happy

    I have not been a fan of Patrick Soon-Shiong and his approach to the biopharma business (and the publicity thereof). There’s a new lawsuit that (should its accusation hold up) will make anyone even less of a fan. Here’s a rundown at Endpoints, and one at Forbes. It’s a mess, so I’ll try to untangle… Read More
  • Academia (vs. Industry)

    Startup Culture, Starting

    Many readers of this blog work in the biopharma industry, naturally, and of those, many are in and around the (few) locations where a great many of the companies in the industry are born. I myself am in the Boston/Cambridge area, famously thick with companies large and small, and then you have the Bay area… Read More
123...